Most newly treated patients with type 2 diabetes exhibit suboptimal medication persistence, which is associated with higher risk of hospitalization and increased medical costs.
Two items in the medical world should send chills down the spines of those considering the possible financial future of oncology care in the United States.
Patients with congestive heart failure and/or chronic obstructive pulmonary disease who had more quarterly primary care visits had lower rates of hospitalizations during the COVID-19 pandemic.
Many clinicians have reported a lack of understanding of the FDA approval process and a desire for strong premarket evidence to support these approvals.
This evaluation looks at a postdischarge digital engagement (PDDE) program using causal inference methods to examine the impact of PDDE on readmission.